会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Self-immolative probes for enzyme activity detection
    • 用于酶活性检测的自发性探针
    • US20120122136A1
    • 2012-05-17
    • US12927497
    • 2010-11-16
    • Maciej SzczepanikIrina V. LebedevaYuejun XiangPraveen PandeWayne Forrest Patton
    • Maciej SzczepanikIrina V. LebedevaYuejun XiangPraveen PandeWayne Forrest Patton
    • C12Q1/26C07D491/22G01N21/75C07D493/10C07D413/14C07D237/32C07D311/08
    • C12Q1/26C07D311/08C07D491/052C07D491/20C07D493/10C09K11/06C09K2211/1022C09K2211/1088C12Q1/37C12Q1/44C12Q1/485G01N2333/902G01N2500/00Y10T436/18
    • Provided is a compound comprising the structure: (SIG)-(SI-MOD)m. In this compound, SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. With this compound, when MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided is a method of determining whether a sample comprises an activator, using the above-described compound. Additionally provided is a method of determining whether a cell comprises a nitroreductase using the above-described compound where nitroreductase is the activator. Further provided is a method of determining whether a mammalian cell is hypoxic using the above-described compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase, using the above-described compound where nitroreductase is the activator, is also provided. Also provided is a method of identifying nitroreductase in a sample, using the above-described compound where nitroreductase is the activator.
    • 提供了包含以下结构的化合物:(SIG) - (SI-MOD)m。 在该化合物中,SIG是信号分子,SI是与SIG结合的自消除结构,使得SIG相对于没有SI的SIG的信号具有降低的信号,MOD是与SI结合的部分,其经受 活化剂,m为1至约10的整数。用该化合物,当MOD被活化剂修饰时,SI是不稳定的并且从SIG自分离,使得SIG产生增加的信号。 还提供了使用上述化合物来确定样品是否包含活化剂的方法。 另外提供了使用上述硝基还原酶是活化剂的化合物来确定细胞是否包含硝基还原酶的方法。 还提供了使用上述硝基还原酶是活化剂的化合物来确定哺乳动物细胞是否缺氧的方法。 还提供了使用上述硝基还原酶为活化剂的化合物检测包含硝基还原酶的微生物的方法。 还提供了使用上述硝酸还原酶是活化剂的化合物来鉴定样品中的硝基还原酶的方法。
    • 10. 发明申请
    • HYDROXYCHOLESTEROL IMMUNOASSAY
    • 羟吗啉酮免疫
    • US20120115169A1
    • 2012-05-10
    • US12927206
    • 2010-11-09
    • Michael C. MullenixRobert Elliot ZipkinJeffrey Kroll AdamsWayne Forrest PattonJames J. Donegan
    • Michael C. MullenixRobert Elliot ZipkinJeffrey Kroll AdamsWayne Forrest PattonJames J. Donegan
    • G01N33/53C07J9/00C07K14/00C07J43/00G01N33/566C07K16/44
    • G01N33/92C07J9/00C07J43/003C07K16/18C07K16/44C07K2317/21G01N33/5308G01N33/56966G01N2800/2835G01N2800/285G01N2800/52
    • Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.
    • 提供了22-羟基胆固醇,24S-羟基胆固醇,25-羟基胆固醇,26-羟基胆固醇或27-羟基胆固醇的衍生物。 还提供了与上述衍生物结合的蛋白质。 进一步提供了包含特异性结合22-羟基胆固醇,24S-羟基胆固醇,25-羟基胆固醇,26-羟基胆固醇或27-羟基胆固醇的抗体的抗体组合物。 此外,提供了制备特异性结合22-羟基胆固醇,24S-羟基胆固醇,25-羟基胆固醇,26-羟基胆固醇或27-羟基胆固醇的抗体的方法。 此外,提供了测定22-羟基胆固醇,24S-羟基胆固醇,25-羟基胆固醇,26-羟基胆固醇或27-羟基胆固醇的方法。 另外提供了用于检测22-羟基胆固醇,24S-羟基胆固醇,25-羟基胆固醇,26-羟基胆固醇或27-羟基胆固醇的试剂盒。 还提供了检测在II期药物代谢中使用的酶或酶的方法。 此外,提供了检测合成22-羟基胆固醇,24S-羟基胆固醇,25-羟基胆固醇,26-羟基胆固醇或27-羟基胆固醇的酶的方法。 进一步提供评估患者多发性硬化症进展的方法。 还提供了确定患者多发性硬化症的治疗是否有效的方法。 此外,提供了评价患者中亨廷顿病进展的方法。 另外提供了一种确定患者亨廷顿氏病的治疗是否有效的方法。